Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119842) titled 'A randomized, single-center, blinded analysis clinical study to evaluate the safety and efficacy of NT-88 in patients with heart failure with chronic mildly reduced ejection fraction' on March 4.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Huizhou Central People's Hospital
Condition:
Heart failure with chronic mildly reduced ejection fraction
Intervention:
Trial Group:Conventional drug therapy + NT-88 (Zuozhudaxi), NT-88 administration: once every 2 days, 4 pills each time, oral administration for 15 times
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enroll...